Skip to main content
logo
OSE Immunotherapeutics SA (EPA:OSE)
France flag France · Delayed Price · Currency is EUR
3.186
-0.020 (-0.62%)
Aug 3, 2026, 2:51 PM CET

OSE Immunotherapeutics Financials Overview

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
2.622.6269.882.2318.326.31
Revenue Growth
21.59%-96.25%3037.72%-87.83%-30.43%152.50%
Gross Profit
2.622.6269.882.2318.326.31
Operating Income
-15.76-37.5630.18-22.99-18.48-16.63
Net Income
-37.69-37.6937.45-23-17.76-16.85
Earnings Per Share
-1.69-1.691.46-1.18-0.96-0.93
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
31.6831.6865.7929.525.6243.43
Total Debt
35.3835.3846.1345.844.7937.13
Net Cash (Debt)
-3.7-3.719.66-16.31-19.176.3
Net Cash Growth
------67.26%
Net Cash Per Share
-0.17-0.170.90-0.83-1.030.35

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-34.03-34.0348.44-19.76-18.25-9.92
Capital Expenditures
-0.1-0.1-0.08-0.02-0.27-0.47
Free Cash Flow
-34.13-34.1348.36-19.78-18.53-10.39
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-601.83%-1434.02%43.19%-1032.15%-100.96%-63.20%
Pretax Margin
-1428.56%-1428.56%57.00%-1042.70%-98.47%-65.43%
Profit Margin
-1439.06%-1439.06%53.59%-1032.91%-97.04%-64.05%
FCF Margin
-1303.25%-1303.25%69.21%-888.19%-101.22%-39.50%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--4.91---
Forward PE
-11.122.8393.6693.6693.66
P/FCF Ratio
--3.25---
PS Ratio
28.0244.092.2537.606.767.09